Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

Annals of Surgical Oncology

Volumn 23, Issue 13, 2016, Pages 4169-4177

  Andtbacka, Robert H I ^a   Ross, Merrick ^b   Puzanov, Igor ^c   Milhem, Mohammed ^d   Collichio, Frances ^e   Delman, Keith A ^f   Amatruda, Thomas ^g   Zager, Jonathan S ^h   Cranmer, Lee ⁱ   Hsueh, Eddy ^j   Chen, Lisa ^k   Shilkrut, Mark ^k   Kaufman, Howard L ^l  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f EMORY UNIVERSITY   (United States)

^g Minnesota Oncology   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j SAINT LOUIS UNIVERSITY CANCER CENTER   (United States)

^k AMGEN INC   (United States)

^l RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TALIMOGENE LAHERPAREPVEC;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN DEFECT; TREATMENT DURATION; TREATMENT RESPONSE; ADRENAL TUMOR; CLINICAL TRIAL; GASTROINTESTINAL TUMOR; HUMAN ALPHAHERPESVIRUS 1; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; KIDNEY TUMOR; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; ONCOLYTIC VIROTHERAPY; PANCREAS TUMOR; PATHOLOGY; SECONDARY; SKIN TUMOR; SPLEEN TUMOR; SURVIVAL RATE; THYROID TUMOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR VOLUME;

ADRENAL GLAND NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HERPESVIRUS 1, HUMAN; HUMANS; INJECTIONS, INTRALESIONAL; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; ONCOLYTIC VIROTHERAPY; PANCREATIC NEOPLASMS; SKIN NEOPLASMS; SPLENIC NEOPLASMS; SURVIVAL RATE; THYROID NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84976308129     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-016-5286-0     Document Type: Article

References (16)

1. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy. 2003;10(4):292–303.
2. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763–71.
3. Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015;33(25):2780–88.
4. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737–47.
5. Hodi FS, Sznol M, Kluger HM, et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. ASCO Meeting Abstracts. 2014 2014;32(15 Suppl):9002.
6. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30.
7. Wolchok JD, Hamid O, Ribas A, et al. Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. ASCO Meeting Abstracts. 2015;33(15 Suppl):3000.
8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–14.
9. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718–30.
10. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20.
11. Megahed A, Faulhaber P, Phillips T, Koon H. Delayed response in ipilimumab therapy. J Community Support Oncol. 2014;12(3):109–10.
12. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541–43.
13. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23(25):6043–53.
14. Gilardi L, Colandrea M, Vassallo S, Travaini LL, Paganelli G. Ipilimumab-induced immunomediated adverse events: possible pitfalls in (18)F-FDG PET/CT interpretation. Clin Nucl Med. 2014;39(5):472–74.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
16. Puzanov I, Milhem MM, Andtbacka RHI, et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. ASCO Meeting Abstracts. 2014 2014;32(15 Suppl):9029.